Experience

EMERGEX VACCINES HOLDING LIMITED
• Head of Immunoproteomics

  • Sep 2020 - Present


ImmProNano LLC

• Team Lead/Co-Founder

  • Jun 2015 - Sep 2020

  • Promoting company proteomic services and aiding in the developing total service package to meet customers’ needs and expectations. • Preparing and presenting technical seminars to potential customers and in major trade shows or scientific conferences. • Project leader in the section of Liquid Chromatography/Mass Spectrometry (LC/MS) responsible for method development/optimization, experiment design/implementation, and data analysis/interpretation. • Promoting company proteomic services and aiding in the developing total service package to meet customers’ needs and expectations. • Preparing and presenting technical seminars to potential customers and in major trade shows or scientific conferences. • Project leader in the section of Liquid Chromatography/Mass Spectrometry (LC/MS) responsible for method development/optimization, experiment design/implementation, and data analysis/interpretation.



Immunotope, Inc.

• United States
• Pharmaceutical Manufacturing

• Senior Scientist

  • Jan 2013 - Jun 2015

  • Screened and identified novel T-cell epitopes as human vaccine candidates by employing quantitative proteomics approaches to analyze well-established in vitro models of human infectious disease(i.e. HBV, Dengue, HTLV, flu, etc.) and cancer (i.e. breast cancer, prostate cancer, colon cancer etc.). • Major role in discovering HLA-A2 or A24-specific epitopes derived from Dengue infected cells, which (naïve or formulated forms) can stimulate CD8+ T-cell response through ELISPOT (enzyme-linked… Show more • Screened and identified novel T-cell epitopes as human vaccine candidates by employing quantitative proteomics approaches to analyze well-established in vitro models of human infectious disease(i.e. HBV, Dengue, HTLV, flu, etc.) and cancer (i.e. breast cancer, prostate cancer, colon cancer etc.). • Major role in discovering HLA-A2 or A24-specific epitopes derived from Dengue infected cells, which (naïve or formulated forms) can stimulate CD8+ T-cell response through ELISPOT (enzyme-linked immunosorbent spot) and MAGPIX assay; those naturally presented epitopes may serve as part of therapeutic vaccine candidates to treat dengue fever or hemorrhage. • Assist with cap particle formulation including preparation, optimization and stability evaluation. • Investigated and characterized chemokine-induced modifications of phosphorylated proteins in dendritic cells by utilizing strategy of iTRAQ-labeled immunoproteomics. • Designed and implemented experiments to explore potential glycopeptides/glycoproteins as therapeutic biomarkers using label free platform for regulating growth and progression of glioblastoma. Show less • Screened and identified novel T-cell epitopes as human vaccine candidates by employing quantitative proteomics approaches to analyze well-established in vitro models of human infectious disease(i.e. HBV, Dengue, HTLV, flu, etc.) and cancer (i.e. breast cancer, prostate cancer, colon cancer etc.). • Major role in discovering HLA-A2 or A24-specific epitopes derived from Dengue infected cells, which (naïve or formulated forms) can stimulate CD8+ T-cell response through ELISPOT (enzyme-linked… Show more • Screened and identified novel T-cell epitopes as human vaccine candidates by employing quantitative proteomics approaches to analyze well-established in vitro models of human infectious disease(i.e. HBV, Dengue, HTLV, flu, etc.) and cancer (i.e. breast cancer, prostate cancer, colon cancer etc.). • Major role in discovering HLA-A2 or A24-specific epitopes derived from Dengue infected cells, which (naïve or formulated forms) can stimulate CD8+ T-cell response through ELISPOT (enzyme-linked immunosorbent spot) and MAGPIX assay; those naturally presented epitopes may serve as part of therapeutic vaccine candidates to treat dengue fever or hemorrhage. • Assist with cap particle formulation including preparation, optimization and stability evaluation. • Investigated and characterized chemokine-induced modifications of phosphorylated proteins in dendritic cells by utilizing strategy of iTRAQ-labeled immunoproteomics. • Designed and implemented experiments to explore potential glycopeptides/glycoproteins as therapeutic biomarkers using label free platform for regulating growth and progression of glioblastoma. Show less



Thomas Jefferson University

• United States
• Higher Education
• 700 & Above Employee

• Postdoc fellow

  • Nov 2010 - Jan 2013

  • Planned and performed experiments to profile global proteomic alterations in tamoxifen-resistant MCF7/BUS human breast cancer cells by employing quantitative proteomics approaches (iTRAQ labelling and 2-dimentional LC/MS using Agilent 6520 QTOF); demonstrated adaptive changes in the proteome of resistant cells which involved cell energy metabolism and microenvironment stabilization; in particular, the dysregulated glucose metabolism pathway was found to play an fundamental role in breast… Show more • Planned and performed experiments to profile global proteomic alterations in tamoxifen-resistant MCF7/BUS human breast cancer cells by employing quantitative proteomics approaches (iTRAQ labelling and 2-dimentional LC/MS using Agilent 6520 QTOF); demonstrated adaptive changes in the proteome of resistant cells which involved cell energy metabolism and microenvironment stabilization; in particular, the dysregulated glucose metabolism pathway was found to play an fundamental role in breast cancer resistance to endocrine therapy. • Developed plasma-based biomarker assays (Multiple Reaction Monitoring) by using ABI 4000 QTRAP for identify and quantify signature peptides/proteins, and applied to potential applications in the prevention and early diagnosis of breast cancer. • Contributed to the project “cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells” by establishing ER-defective MCF7/BUS cells whose estrogen receptors were knocked down and investigating cell migration under various conditions with real time imaging system. Show less • Planned and performed experiments to profile global proteomic alterations in tamoxifen-resistant MCF7/BUS human breast cancer cells by employing quantitative proteomics approaches (iTRAQ labelling and 2-dimentional LC/MS using Agilent 6520 QTOF); demonstrated adaptive changes in the proteome of resistant cells which involved cell energy metabolism and microenvironment stabilization; in particular, the dysregulated glucose metabolism pathway was found to play an fundamental role in breast… Show more • Planned and performed experiments to profile global proteomic alterations in tamoxifen-resistant MCF7/BUS human breast cancer cells by employing quantitative proteomics approaches (iTRAQ labelling and 2-dimentional LC/MS using Agilent 6520 QTOF); demonstrated adaptive changes in the proteome of resistant cells which involved cell energy metabolism and microenvironment stabilization; in particular, the dysregulated glucose metabolism pathway was found to play an fundamental role in breast cancer resistance to endocrine therapy. • Developed plasma-based biomarker assays (Multiple Reaction Monitoring) by using ABI 4000 QTRAP for identify and quantify signature peptides/proteins, and applied to potential applications in the prevention and early diagnosis of breast cancer. • Contributed to the project “cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells” by establishing ER-defective MCF7/BUS cells whose estrogen receptors were knocked down and investigating cell migration under various conditions with real time imaging system. Show less



Waters

• United Kingdom
• Graphic Design
• 1 - 100 Employee

• Analytical chemist

  • Aug 2002 - May 2004

  • Demonstrated HPLC and LCMS systems which comply with GLP or cGMP guidelines for both academic and industrial clients. • Familiar with regulatory requirement for analytical device such as 21CFR Part 11 and ER/ES (electronic signature/record). • Consulted with customers, distributors and local subsidiaries by phone and in person to provide pre-sales and post-sales technical support. compliance & Empower software. • Demonstrated HPLC and LCMS systems which comply with GLP or cGMP guidelines for both academic and industrial clients. • Familiar with regulatory requirement for analytical device such as 21CFR Part 11 and ER/ES (electronic signature/record). • Consulted with customers, distributors and local subsidiaries by phone and in person to provide pre-sales and post-sales technical support. compliance & Empower software.



National University of Singapore

• Singapore
• Higher Education
• 700 & Above Employee

• Research Associate

  • Sep 1999 - Aug 2002

  • Established a sensitive and selective micro-assay for detecting selective serotonin reuptake inhibitors(SSRIs) and their metabolites in human plasma and breast milk. • Studied pharmacokinetics of SSRIs in breast feeding mice and drug-drug interaction via equilibrium dialysis. • Created a mathematical model which predicted the potential risk to neonates when exposing to maternal antidepressant treatment • Established a sensitive and selective micro-assay for detecting selective serotonin reuptake inhibitors(SSRIs) and their metabolites in human plasma and breast milk. • Studied pharmacokinetics of SSRIs in breast feeding mice and drug-drug interaction via equilibrium dialysis. • Created a mathematical model which predicted the potential risk to neonates when exposing to maternal antidepressant treatment



3rd Affiliated Hospital of Peking University

• Clinical Pharmacist

  • Aug 1995 - Jul 1999

  • Participated in bioavailability studies of Isosorbide-5-mononitrate Controlled-release Tablets in human subjects; active role in recruiting healthy volunteers, blood sample collection & analysis, document preparation; • Designed and performed the bio-equivalence tests of Celiprolol and Pantoprazole; • Provided contract-based bio-equivalence services for pharmaceutical and biotech companies using HPLC and CE platform. • Participated in bioavailability studies of Isosorbide-5-mononitrate Controlled-release Tablets in human subjects; active role in recruiting healthy volunteers, blood sample collection & analysis, document preparation; • Designed and performed the bio-equivalence tests of Celiprolol and Pantoprazole; • Provided contract-based bio-equivalence services for pharmaceutical and biotech companies using HPLC and CE platform.